Document Detail


Pharmacotherapy of Zollinger-Ellison syndrome.
MedLine Citation:
PMID:  23363383     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The role of pharmacotherapy in the management of patients with Zollinger-Ellison syndrome (ZES) is often equated with the medical management of acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients.
AREAS COVERED: This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is the role of pharmacotherapy in controlling acid hypersecretion and other hormonal hypersecretory states these patients may develop, including hyperparathyroidism in patients with multiple endocrine neoplasia type 1 and ZES; tumor localization; and the treatment of advanced metastatic disease. The last includes chemotherapy, liver-directed therapies, biotherapy (somatostatin/interferon), peptide radio-receptor therapy and molecular-targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib).
EXPERT OPINION: Pharmacotherapy is now involved in all aspects of the management of patients with ZES, with the result that ZES has progressed from being considered an entirely surgical disease initially to the present where medical treatment plays a major role in almost all aspects of the management of these patients.
Authors:
Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Related Documents :
11977163 - Cerebro-osseous-digital syndrome: four new cases of a lethal skeletal dysplasia--distin...
23439263 - Lessons from look-back in acute liver failure? a single centre experience of 3300 patie...
1918413 - Cerebrospinal fluid concentration of fibronectin in meningitis.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review     Date:  2013-01-30
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  14     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-04     Completed Date:  2013-07-22     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  307-21     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Gastric Acid / secretion
Gastrinoma / drug therapy*,  etiology,  pathology
Humans
Hyperparathyroidism / drug therapy,  etiology
Molecular Targeted Therapy
Neoplasm Metastasis
Pancreatic Neoplasms / drug therapy*,  etiology,  pathology
Proton Pump Inhibitors / therapeutic use
Zollinger-Ellison Syndrome / diagnosis,  drug therapy*,  pathology
Grant Support
ID/Acronym/Agency:
Z99 DK999999/DK/NIDDK NIH HHS; ZIA DK053200-21/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Proton Pump Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  On the cellular and molecular regulatory transcriptional mechanisms and responsive putative pathways...
Next Document:  The Biology of Hair Diversity.